NKGen Biotech (NKGN) announced that its Chairman & Chief Executive Officer, Paul Y. Song, M.D., has invested $2.65 million cash, derived from the recent successful sale of another biotech business Dr. Song co-founded, in an effort to accelerate the Company’s Phase 2 clinical trial for Alzheimer’s Disease, reduce Company payables and cover additional general working capital and public company compliance-related expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.